CeriBell (NASDAQ:CBLL) Now Covered by Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of CeriBell (NASDAQ:CBLL) in a research note issued to investors on Tuesday, Briefing.com reports. The brokerage set an “overweight” rating and a $32.00 price target on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 21.95% from the stock’s current price.

Several other analysts have also recently issued reports on the company. William Blair started coverage on CeriBell in a report on Tuesday. They set an “outperform” rating on the stock. TD Cowen started coverage on shares of CeriBell in a report on Tuesday. They issued a “buy” rating and a $31.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.25.

CeriBell Stock Performance

CBLL opened at $26.24 on Tuesday. CeriBell has a 52 week low of $23.00 and a 52 week high of $27.71.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.